COMP <GO>
HRMY vs ABBV // EV/EBITDA & P/E VALUATION
Harmony Biosciences Holdings Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HRMY 9
— ABBV 4
▲ EV/EBITDA & P/E VALUATION LEADER: HRMY
LAST: $38.59 (+0.23%) • MKT CAP: $2.25B
valuation
7.8x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRMY VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HRMY | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.20% | 70.20% | +7.00 | HRMY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.00% | 29.00% | +34.00 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.8x | 33.3x | -25.50 | HRMY | /valuation <GO> |
| Free Cash Flow Yield | 15.48% | 3.47% | +12.01 | HRMY | /fcf-yield <GO> |
| Operating Margin | 24.00% | 24.60% | -0.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 6.90% | +11.40 | HRMY | /net-margins <GO> |
| Revenue Growth (YoY) | 21.50% | 8.60% | +12.90 | HRMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.38 | 5.33 | +0.05 | HRMY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 65.1 | -14.04 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 113.1x | -101.20 | HRMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.25B | $513.86B | -$511.61B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HRMY REV | ABBV REV | HRMY GROSS % | ABBV GROSS % | HRMY FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $868.5M | $61.16B | 77.2% | 70.2% | $347.9M | $17.82B |
| FY 2024 | $714.7M | $56.33B | 78.1% | 70.0% | $218.7M | $17.83B |
| FY 2023 | $582.0M | $54.32B | — | — | $219.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRMY // BETA —
ABBV // BETA 1.15